Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc.

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Fennec Pharmaceuticals, with a price target of $20.00. M...

Fennec Pharmaceuticals (FENC) Gets a Buy from Maxim Group

Wedbush analyst maintained a Buy rating on Fennec Pharmaceuticals today and set a price target of $16.00. In a report released today, Craig-Hallum ...

Fennec Pharmaceuticals (FENC) Gets a Buy from Wedbush

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fennec Pharmaceuticals (FENC) and Immunome (IMNM) wi...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FENC	$12.39	-1.27%	212.44K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FENC	$12.39	-1.3%	212.44K
3
4
5
6

FENC

Get Fennec Pharmaceuticals Inc. Data in Excel

Get Fennec Pharmaceuticals Inc. Data in Excel